268 related articles for article (PubMed ID: 24408225)
1. Rituximab fails where eculizumab restores renal function in C3nef-related DDD.
Rousset-Rouvière C; Cailliez M; Garaix F; Bruno D; Laurent D; Tsimaratos M
Pediatr Nephrol; 2014 Jun; 29(6):1107-11. PubMed ID: 24408225
[TBL] [Abstract][Full Text] [Related]
2. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.
Ozkaya O; Nalcacioglu H; Tekcan D; Genc G; Meydan BC; Ozdemir BH; Baysal MK; Keceligil HT
Pediatr Nephrol; 2014 Jul; 29(7):1283-7. PubMed ID: 24464478
[TBL] [Abstract][Full Text] [Related]
3. Eculizumab in Pediatric Dense Deposit Disease.
Oosterveld MJ; Garrelfs MR; Hoppe B; Florquin S; Roelofs JJ; van den Heuvel LP; Amann K; Davin JC; Bouts AH; Schriemer PJ; Groothoff JW
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1773-82. PubMed ID: 26316621
[TBL] [Abstract][Full Text] [Related]
4. C3 glomerulopathy and eculizumab: a report on four paediatric cases.
Lebreton C; Bacchetta J; Dijoud F; Bessenay L; Fremeaux-Bacchi V; Sellier-Leclerc AL
Pediatr Nephrol; 2017 Jun; 32(6):1023-1028. PubMed ID: 28236143
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
Le Quintrec M; Lapeyraque AL; Lionet A; Sellier-Leclerc AL; Delmas Y; Baudouin V; Daugas E; Decramer S; Tricot L; Cailliez M; Dubot P; Servais A; Mourey-Epron C; Pourcine F; Loirat C; Frémeaux-Bacchi V; Fakhouri F
Am J Kidney Dis; 2018 Jul; 72(1):84-92. PubMed ID: 29429752
[TBL] [Abstract][Full Text] [Related]
6. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment.
Kaartinen K; Martola L; Räisänen-Sokolowski A; Meri S
Clin Immunol; 2018 Feb; 187():104-106. PubMed ID: 29097196
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease.
Tran CL; Sethi S; Murray D; Cramer CH; Sas DJ; Willrich M; Smith RJ; Fervenza FC
Pediatr Nephrol; 2016 Apr; 31(4):683-7. PubMed ID: 26759144
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
9. Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression.
Häffner K; Michelfelder S; Pohl M
Pediatr Nephrol; 2015 Nov; 30(11):1951-9. PubMed ID: 25986912
[TBL] [Abstract][Full Text] [Related]
10. C3 nephritic factor associated with C3 glomerulopathy in children.
Nicolas C; Vuiblet V; Baudouin V; Macher MA; Vrillon I; Biebuyck-Gouge N; Dehennault M; Gié S; Morin D; Nivet H; Nobili F; Ulinski T; Ranchin B; Marinozzi MC; Ngo S; Frémeaux-Bacchi V; Pietrement C
Pediatr Nephrol; 2014 Jan; 29(1):85-94. PubMed ID: 24068526
[TBL] [Abstract][Full Text] [Related]
11. A CHILD WITH DENSE DEPOSIT DISEASE AND DECREASED CLASSIC COMPLEMENT PATHWAY ACTIVITY.
Trutin I; Oletić L; Galešić Ljubanović D; Turudić D; Milošević D
Acta Clin Croat; 2021 Mar; 60(1):141-145. PubMed ID: 34588735
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab and recurrent C3 glomerulonephritis.
Gurkan S; Fyfe B; Weiss L; Xiao X; Zhang Y; Smith RJ
Pediatr Nephrol; 2013 Oct; 28(10):1975-81. PubMed ID: 23689905
[TBL] [Abstract][Full Text] [Related]
13. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
[TBL] [Abstract][Full Text] [Related]
14. C3 glomerulopathy.
Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
[TBL] [Abstract][Full Text] [Related]
15. Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy.
Giaime P; Daniel L; Burtey S
Clin Nephrol; 2015 Jan; 83(1):57-60. PubMed ID: 24472365
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab for dense deposit disease and C3 glomerulonephritis.
Bomback AS; Smith RJ; Barile GR; Zhang Y; Heher EC; Herlitz L; Stokes MB; Markowitz GS; D'Agati VD; Canetta PA; Radhakrishnan J; Appel GB
Clin J Am Soc Nephrol; 2012 May; 7(5):748-56. PubMed ID: 22403278
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab for pediatric dense deposit disease: A case report and literature review.
Kasahara K; Gotoh Y; Majima H; Takeda A; Mizuno M
Clin Nephrol Case Stud; 2020; 8():96-102. PubMed ID: 33329990
[TBL] [Abstract][Full Text] [Related]
18. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.
Leroy V; Fremeaux-Bacchi V; Peuchmaur M; Baudouin V; Deschênes G; Macher MA; Loirat C
Pediatr Nephrol; 2011 Mar; 26(3):419-24. PubMed ID: 21188423
[TBL] [Abstract][Full Text] [Related]
19. C3 glomerulopathy: A new complement-based entity.
de Lorenzo A; Tallón S; Hernández-Sevillano B; de Arriba G
Rev Clin Esp (Barc); 2014; 214(5):266-74. PubMed ID: 24576419
[TBL] [Abstract][Full Text] [Related]
20. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]